Brand,Molecule,Indication,Approval_Date,Notes
Ozempic,semaglutide,Type 2 diabetes,12/5/2017,FDA label initial approval (NDA 209637)
Rybelsus,semaglutide (oral),Type 2 diabetes,9/20/2019,FDA approval (NDA 213051)
Wegovy,semaglutide,Chronic weight management (obesity/overweight),6/4/2021,FDA approval (BLA/NDA 215256)
Mounjaro,tirzepatide,Type 2 diabetes,5/13/2022,FDA approval (BLA/NDA 215866)
Zepbound,tirzepatide,Chronic weight management (obesity/overweight),11/8/2023,FDA approval (tirzepatide for obesity)
Zepbound,tirzepatide,Obstructive Sleep Apnea (in adults with obesity),12/20/2024,FDA expanded indication (OSA)
